MedTrace Logo

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

NCT05755854 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-09-22

No results posted yet for this study

Summary

This is an open single-arm clinical study aimed at evaluating the safety and tolerance of allogeneic γ9δ2 T cell injection in the treatment of patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation.

Conditions

Interventions

BIOLOGICAL

allogeneic γ9δ2 T Cells

dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)

DRUG

Fludarabine

Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition

DRUG

Cyclophosphamide

Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition

DRUG

Zoredronic acid

Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Zhu Xiaoyu, Ph.D · Director of Hematology Department, Anhui Provincial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05755854 on ClinicalTrials.gov